Results 61 to 70 of about 84,688 (355)

Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry

ESC Heart Failure, 2020
Aims In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure (HF) was released. The aim of this study was to describe the management of HF with reduced ejection fraction after the publication ...
Fernando deFrutos, Sonia Mirabet, Luis Ortega‐Paz, Irene Buera, Sara Darnés, Nuria Farré, Bernardo Perez, Raquel Adeliño, Ramón Bascompte, Jordi Pérez‐Rodón, Xavier Aparicio, Mario Sutil‐Vega, Adriana Soto, Mercedes Faraudo, Miguel Cainzos‐Achirica, Nicolás Manito   +15 more
doaj   +1 more source

Temporal trends in heart failure medication prescription in a population-based cohort study

BMJ Open, 2021
Objective We examined temporal heart failure (HF) prescription patterns in a large representative sample of real-world patients in the UK, using electronic health records (EHR).Methods From primary and secondary care EHR, we identified 85 732 patients ...
Ilonca Vaartjes, Harry Hemingway, Anoop Shah, Folkert W Asselbergs, S Denaxas, J Cleland, Alicia Uijl, Diederick Grobbee, Arno Hoes, Stefan Koudstaal   +9 more
doaj   +1 more source

Physiological monitoring in the complex multimorbid heart failure patient - Conclusions. [PDF]

, 2019
Comorbidities are increasingly recognized as crucial components of the heart failure syndrome. Main specific challenges are polypharmacy, poor adherence to treatments, psychological aspects, and the need of monitoring after discharge.
Böhm, M, Coats, AJS, Kindermann, I, Rosano, G, Spoletini, I   +4 more
core   +1 more source

F‐Box and Leucine‐Rich Repeat Protein 4 (FBXL4) Maintains Sarcomere Integrity and Cardiac Function by Enhancing K48‐Linked Ubiquitinated Degradation of Profilin‐1 (PFN1)

Advanced Science, EarlyView.
Schematic diagram depicting the proposed signaling mechanisms underlying the effects of FBXL4 in the setting of cardiac hypertrophy. Under hypertrophic stimulation, cardiomyocytes‐specific overexpression FBXL4 maintains sarcomere integrity and cardiac function by enhancing K48‐linked ubiquitinated degradation of PFN1 at the K70 site.
Xingda Li, Xueqi He, Xinyuan Hao, Yu Zhang, Xin Zhao, Shuang Wang, Zhenru Wang, Haonan Du, Hongda Li, Lian Yi, Zhimin Du, Weijie Du   +11 more
wiley   +1 more source

Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma [PDF]

, 2002
No abstract ...
Bray, C.A., Hole, D.J., Mackie, R.M.
core   +2 more sources

SETDB2 Mitigates Podocyte Dysfunction in Diabetic Kidney Disease Through Epigenetic Silencing of SMAD3

Advanced Science, EarlyView.
SETDB2 epigenetically represses Smad3 transcription by increasing H3K9me3 enrichment at its promoter, thereby mitigating podocyte dysfunction in DKD. The transcription factor TCF21 binds directly to the Setdb2 promoter and enhances its expression in podocytes. Abstract Podocyte dysfunction represents both an early pathological hallmark and a key driver
Lanfang Li, Shimin Jiang, Qi Jin, Peng Qu, Yingjie Guo, Xushan Lan, Xinyu Li, Cuiting Sun, Sinan Ai, Xin Li, Weiliang Sun, Jing Guo, Wenge Li, Liang Peng, Lihong Liu   +14 more
wiley   +1 more source

G protein coupled receptors of the renin-angiotensin system: new targets against breast cancer?

Frontiers in Pharmacology, 2015
G-protein coupled receptors (GPCRs) constitute the largest family of membrane receptors, with high potential for drug discovery. These receptors can be activated by a panel of different ligands including ions, hormones, small molecules and vasoactive ...
Clara eNAHMIAS, Sylvie eRODRIGUES-FERREIRA   +1 more
doaj   +1 more source

Evaluation of machine-learning methods for ligand-based virtual screening [PDF]

, 2007
Machine-learning methods can be used for virtual screening by analysing the structural characteristics of molecules of known (in)activity, and we here discuss the use of kernel discrimination and naive Bayesian classifier (NBC) methods for this purpose ...
A Bender, A Bender, A Bender, A Ormerod, A Ormerod, AE Klon, AM Capelli, AR Leach, B Chen, Beining Chen, C Williams, D Hand, D Rogers, D Wilton, DA Cosgrove, David J. Wood, DB Kitchen, DE Clark, DJ Hand, DJ Wilton, DM Hawkins, E Parzen, FL Stahura, G Harper, G Redl, G Schneider, George Papadatos, H Eckert, H Kubinyi, HM Berman, J Aitchison, J Bajorath, J Delaney, J Hert, J Hert, J Hert, JC Saeh, L Hodes, L Hodes, L Hodes, M Congreve, M Glick, M Glick, M Wagener, M Whittle, N Christianini, N Nikolova, Nikolaus Stiefl, P Constans, P Domingos, P Willett, P Willett, P Willett, P Willett, P Willett, Paulette Greenidge, Peter Willett, Q Zhang, R P Sheridan, RD Brown, RD Brown, RD Cramer, RE Carhart, RO Duda, Robert F. Harrison, S Anzali, TJ McNeany, TM Mitchell, Xiao Qing Lewell, XY Xia, YC Martin, YC Martin   +71 more
core   +2 more sources

Comparison of angiotensin II receptor antagonists [PDF]

European Journal of Clinical Investigation, 2001
Nonpeptide orally active angiotensin II type 1 (AT1) receptor antagonists are the most specific means presently available to block the renin‐angiotensin enzymatic cascade. Six of these drugs have already been licensed in Europe and in the United States for the treatment of high blood pressure, and additional candidates are in the pipeline.
W, Kirch, B, Horn, J, Schweizer
openaire   +2 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source